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Abstract The antioxidant effect of melatonin on LDL oxida-
tion was studied in vitro using either a thermolabile initiator or 
copper ions to induce lipid peroxidation. Loading of LDL with 
melatonin showed only weak protection against oxidative 
damage as compared to rx-tocopherol. In the presence of high 
concentrations of melatonin (1000 mol/mol LDL) in the medium 
a clear protective effect was found during lag- and propagation 
phase, albeit weaker than after loading with a-tocopherol. It is 
concluded that melatonin is not incorporated into LDL in 
sufficient concentrations to prevent lipid peroxidation effectively. 
When melatonin is present in the incubation medium during 
oxidation, a partitioning equilibrium between aqueous and lipid 
phase is established. Only under these conditions can melatonin 
act as a chain breaking antioxidant. The concentrations required, 
however, are far beyond those found in human plasma. There-
fore, the data in this study do not support a direct physiological 
relevance of melatonin as an antioxidant in lipid peroxidation 
processes. 
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1. Introduction 
Cumulative neuronal insults associated with free radical 
production have been associated with the process of aging. 
The pineal hormone melatonin exhibits some radical scaveng-
ing effects [1], and its secretion declines progressively with age 
[2] leading to the hypothesis that it may protect against age-
related processes, in part by attenuating the effects of free 
radical-induced neuronal damage [3]. 
More recently, several effects of melatonin were attributed 
to its antioxidative properties: cataract induction in rats as a 
consequence of free radical attack on lenticular macromole-
cules could be prevented by in vivo melatonin treatment [4], 
melatonin significantly decreased the frequency of radiation-
induced chromosomal damage in lymphocytes [5,6], and a 
concentration-dependent protection by melatonin against in 
vitro kainic acid-induced oxidative damage was demonstrated 
in different rat brain regions [7-10]. 
Moreover, it was shown that melatonin is a potent radical 
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scavenger, both for hydroxyl [11] and peroxyl radicals [12]. 
There are studies investigating the antioxidant activity of mel-
atonin in lipid model systems [13] and also in human low-
density lipoprotein (LDL) [14]. The results of the latter indi-
cate that melatonin is able to scavenge the lipid peroxyl rad-
icals which propagate the chain reaction of lipid peroxidation. 
These studies, however, leave some doubts as to the extent of 
the reported radical scavenging potential of melatonin: the 
concentrations of melatonin required were rather high and 
the effects comparatively small. 
Preliminary data showed an association between impaired 
nocturnal secretion of melatonin and coronary artery disease 
([15], Sakotnik et al., submitted). Hence, in the present study 
we examine the question, whether melatonin can protect hu-
man L D L against free radical induced lipid peroxidation in 
vitro, the characteristics of which have been extensively inves-
tigated (for a review, see [17]). 
2. Materials and methods 
AAPH (2,2'-azobis(amidinopropane hydrochloride)) was purchased 
from PolySciences Inc. (Warrington, USA), RRR-a-tocopherol from 
Henkel. All other chemicals used were purchased from Merck or 
Sigma (Vienna, Austria) and were of analytical grade, or better. 
LDL was prepared from pooled EDTA plasma by ultracentrifuga-
tion using a single-step discontinuous gradient in a Beckman NVT65 
rotor, as described previously [17]. LDL concentration was deter-
mined from its cholesterol content, using the CHOD-PAP enzymatic 
test kit (Boehringer-Mannheim, Germany), assuming a molar mass of 
2.5 MDa and a cholesterol content of 32.2 weight %. 
2.1. Loading of LDL with antioxidants 
Pooled EDTA plasma was incubated with ethanolic melatonin 
(250 mM, 1% of total plasma volume) at 37°C under argon in the 
dark and LDL was subsequently isolated with the technique described 
above. As a positive control an ethanolic solution of RRR-a-
tocopherol (250 mM, 1% of total plasma volume) was used, and as 
a negative control the same amount of pure ethanol [18]. 
2.2. Direct addition of melatonin to LDL 
An ethanolic solution of melatonin was added to the oxidation 
mixture to give a total ethanol concentration of 0.5% (v/v). In blanks 
the same amount of pure ethanol was used. 
2.3. Induction of LDL lipid peroxidation 
2.3.1. AAPH-mediated LDL oxidation. LDL oxidation was per-
formed at 37°C by addition of an aqueous solution of AAPH to a 
solution of 2 or 1 mg/mL LDL (total mass) to give a final AAPH-
concentration of 1 mM. Decomposition of AAPH is slow enough to 
ensure a constant rate of peroxyl radical formation for several hours. 
Because both melatonin and AAPH exhibit considerable UV-absorp-
tion, which would have interfered with monitoring CD formation, we 
monitored oxygen consumption instead, using a Clark-electrode (Oxy-
graph, A. Paar, Austria). Oxygen consumption of blank AAPH so-
lutions was subtracted. The effect of melatonin alone on oxygen con-
sumption was negligible. 
2.3.2. Copper-mediated LDL oxidation. Prior to oxidation, EDTA 
and KBr were removed by gel-filtration as described [19]. LDL oxi-
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dation was performed at 37°C by addition of a 100 uM solution of 
CuS04 to a 0.1 |iM solution of LDL in PBS (160 mM NaCl, 10 mM 
Na-phosphate, pH = 7.4), to give a final concentration of 1.6 uM. 
Progress of oxidation was monitored by following the formation of 
conjugated dienes (CD) spectrophotometrically (Beckman DU640 
spectrophotometer, equipped with Peltier-thermostatted six-cell hold-
er) at a wavelength of 234 nm [19]. 
2.3.3. Radical scavenging with DPPH (1 ,l-diphenly-2-picrylhydra-
zyl). The ability of melatonin to scavenge free radicals was tested 
with the stable free radical DPPH [20]. To an ethanolic solution of 
DPPH (0.2 mg/mL) 100 uM melatonin or tocopherol were added and 
the formation of the reduced form of DPPH was monitored at 517 nm 
in the spectrophotometer. 
2.4. Determination of melatonin in LDL after incubation and 
reisolation 
To 0.5 mg/mL LDL in PBS 50 uL EDTA (100 mg/mL) and 1 mL 
ethanol (containing 1 mg/mL BHT) were added. After extraction with 
2 mL hexane, 1.2 mL of the hexane phase were evaporated in vacuo. 
The residue was dissolved in the eluent for HPLC, and chromato-
graphed according to [21], using fluorescence detection at 290 nm/ 
357 nm (ex/em) with external standardization. 
2.5. Determination of copper-reduction with bathocuproine disulfonic 
acid 
Reduction of Cu2+ by tocopherol and melatonin was monitored in 
50 vol. % ethanol with bathocuproine disulfonic acid (BCSA, Sigma-
Aldrich, Vienna, Austria). BCSA selectively chelates Cu+ ions by 
formation of a colored, redox-inactive complex, Cu(I)(BCSA)2 
(e48o = 13 500 M
_ 1 cm"1 [22]). The test contained 50 uM of a-tocoph-
erol, melatonin or both. BCSA concentration was 500 uM and the 
reaction was started by adding 100 uM CUSO4. 
2.5.1. Determination of lag-time and propagation rate. Lag-time 
was determined as the time-coordinate of the intersection of the tan-
gents to the increase in CD or decrease of oxygen concentration dur-
ing lag- and propagation phase, as described [19]. Propagation rate is 
defined as the (maximal) rate of formation of CD or consumption of 
oxygen, respectively. 
3. Results 
Loading of LDL with cc-tocopherol is an efficient means to 
increase the content of this endogenous, lipophilic antioxi-
dant, which consequently leads to a significant prolongation 
of the lag-phase [18,20,24]. Because of the reported lipophil-
icity of melatonin [25] we attempted to load LDL with mela-
tonin by the same procedure. 
We investigated the effect of melatonin on AAPH-induced 
LDL oxidation: AAPH initiates lipid peroxidation by decom-
posing thermally into two carbon-centered radicals which are 
subsequently rapidly oxygenated to form the initiating peroxyl 
radicals. Fig. 1 shows the changes in lag-time and propagation 
rates, obtained from oxygen consumption, both in the case of 
pre-incubation of LDL with melatonin and tocopherol, as 
well as the effect of direct addition to the oxidation mixture. 
Pre-incubation with melatonin increased lag-time only mar-
ginally by 11% (total lag-time 39 min) and did not signifi-
Table 1 
Effect of plasma preincubation with melatonin or tocopherol on 
LDL oxidation 
0.6 
Lag-time (min) % Change in lag-time 
Control 
Melatonin 
a-Tocopherol 
80.8 ±0.92 
86.3 ±1.96 
128.8 ±6.33 
6.75 ±1.67 
61.1 ±7.43 
Pooled plasma was preincubated with an ethanolic solution of either 
melatonin or oe-tocopherol (250 mM, 1% v/v added). Controls were 
preincubated with the same amount of pure ethanol. Data are 
mean ± S.E.M. of 3^1 measurements. 
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Fig. 1. Relative changes in lag-time and propagation rate for 
AAPH-mediated oxidation in the presence of melatonin and oc-to-
copherol. A 0.1 uM solution of LDL in PBS was oxidized with 
1 mM AAPH at 37°C. Oxidation was monitored by measuring oxy-
gen consumption. Melatonin was either added at the indicated con-
centrations or LDL was loaded with either melatonin or a-tocoph-
erol. For the controls, pure ethanol was added in the appropriate 
concentration either directly to the incubation or during preincuba-
tion of plasma. Blank oxygen consumption by AAPH was sub-
tracted in every case. 
cantly reduce propagation rate. In contrast, loading with a-to-
copherol as a positive control prolonged lag-time by 49% 
(total lag-time 52 min). The control showed a lag-time of 
35 min and maximum oxygen consumption of 21.7 nM s_ 1 
- the difference compared to the control in the pre-incubation 
experiment is due to the presence of ethanol: in the preincu-
bation experiment practically no ethanol should be present 
during oxidation, as it is removed during LDL isolation. In 
the case of direct addition, the control (0.5% ethanol) showed 
a lag-phase of 51 min and maximum oxygen consumption of 
54.9 nM s_1. Increasing concentrations of melatonin did not 
significantly change lag-time, but melatonin at 25 |iM de-
creased the rate of propagation to 60% of the control 
(33.0 nM s - 1) . While the effect of tocopherol is limited to 
the lag-phase exclusively, the effects of melatonin can be ob-
served during both lag- and propagation-phase. 
In copper-mediated LDL oxidation, lipid peroxyl radicals 
are generated indirectly within the lipid phase [26]. Table 1 
gives a summary of the effects of incubation with melatonin or 
tocopherol of Cu2+-induced LDL oxidation, respectively. Fig. 
2 shows one representative experiment: it is obvious that 
'loading' with melatonin had no significant effect. 
In contrast to this, direct addition of melatonin to the ox-
idation mixture significantly suppressed Cu2+-mediated oxida-
tion as shown in Fig. 3. Melatonin in 50 to 1000-fold molar 
excess (5-100 |0.M) increased lag-time in a concentration-de-
pendent fashion, up to 20%. In addition, maximum rate of 
CD formation, as well as the total maximum amount of CD 
formed, decreased by up to 20% for melatonin concentrations 
of 50 uM or higher, also depending on concentration. Since 
0.5% of ethanol itself produced a significant increase in lag-
time and a decrease in propagation rate, care was taken to use 
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Fig. 2. Effect of plasma incubation with melatonin and a-tocopherol 
on copper-mediated LDL oxidation. Plasma was loaded with either 
melatonin or a-tocopherol or with pure ethanol as a control. After 
isolation, 0.1 |i.M LDL was oxidized with 1.6 pM CUSO4, and for-
mation of conjugated dienes recorded at 234 nm. A significant pro-
longation of lag-time was observed for LDL from plasma incubated 
with a-tocopherol while only a small effect was found after incuba-
tion with melatonin. 
the same concentration of ethanol in all experiments, and 
therefore LDL oxidation in the presence of 0.5% ethanol 
was used as a blank. The same result as in Fig. 3 was obtained 
in experiments where the ethanol concentration was only 
0.05%, thus excluding a direct melatonin-solubilizing effect 
of ethanol in LDL (not shown). 
These results indicate that much less melatonin might be 
incorporated into LDL than expected. Consequently, melato-
nin concentration in 'melatonin-loaded' LDL, as estimated by 
HPLC, was below 0.05 mol melatonin per mol LDL (data not 
shown). 
To exclude the possibility of a redox-inactivation of copper 
(e.g. by chelation) by melatonin, we compared the reduction 
of copper by tocopherol and melatonin in presence of BCSA, 
a selective chelator for Cu+, in 50%) ethanol. Melatonin is a 
weak reductant for copper - it took 15 min to reduce 50 pM 
Cu2+ under our assay conditions (50 uM reductant, 100 pM 
Cu2+). Tocopherol alone reduced copper very rapidly - within 
10 s required for addition of copper, reduction was complete. 
Reduction of copper by 50 pM tocopherol in presence of 
50 uM melatonin was equally rapid, indicating that no re-
dox-inactivation of copper by melatonin occurs. 
Compared to a-tocopherol, the radical scavenging potential 
of melatonin, tested by its ability to scavenge DPPH radicals, 
is negligible: while DPPH was scavenged completely by a-to-
copherol, no significant consumption of DPPH by melatonin 
was observed (Fig. 4). 
4. Discussion 
Lipid peroxidation in LDL performed under the conditions 
described, usually exhibits three phases: (i) a lag-phase with 
very slow formation of conjugated dienes (CD), during which 
endogenous lipophilic antioxidants such as a-tocopherol pre-
vent radical chain propagation. After consumption of these 
endogenous antioxidants, (ii) chain propagation starts which 
is accompanied by a rapid increase in CD formation. Later in 
the process, (iii) CD are destroyed in subsequent reactions 
[24]. The length of the lag-phase represents an accepted meas-
ure for the resistance of LDL to oxidation and thus the effect 
of endogenous antioxidants. In contrast to endogenous anti-
oxidants, amphiphilic antioxidants from the aqueous phase 
can extend their effect to the propagation phase, i.e. they 
will lower the rate of propagation. 
Pre-incubation with a-tocopherol increases its content in 
LDL by a factor of two and more [18,23,24], which results 
in a considerable increase of lag-time. In contrast, attempts to 
load LDL with melatonin had almost no effect, both in 
AAPH- and Cu2+-mediated oxidation, even though melatonin 
has been reported to be both lipophilic and a potent radical 
scavenger. Determination of melatonin in LDL after loading 
showed only minute quantities present excluding accumula-
tion and persistence of melatonin in the lipid phase of LDL. 
In contrast, direct addition of melatonin to the oxidation 
assay, at up to 1000-fold excess over LDL, led to a significant 
antioxidative effect comparable to the results of others [14], 
i.e. lag-times were prolonged, and propagation rates were low-
er. However, our data show that melatonin acts over the 
entire oxidation time, on both AAPH- and Cu2+-mediated 
oxidation, and not predominantly during the lag-phase, 
when endogenous antioxidants of LDL, such as a-tocopherol, 
are effective. Thus, at the end of the lag-phase, when highly 
potent endogenous antioxidants of LDL are already con-
sumed, melatonin still has a retarding effect. 
In case of AAPH-mediated oxidation, melatonin might 
scavenge AAPH-derived peroxyl radicals directly in the aque-
ous medium, thus reducing rate of initiation. However, a sim-
ilar effect of melatonin is also observable in copper-mediated 
oxidation, where lipid peroxyl radicals are generated indirectly 
I I 1 I 
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Fig. 3. Effect of direct addition of melatonin on copper-mediated 
LDL oxidation. The indicated concentration of melatonin was 
added to a solution of 0.1 |xM LDL in PBS and oxidation started 
by addition of 1.6 uM CuS04. Oxidation was monitored by the ab-
sorption of conjugated dienes at 234 nm. Addition of increasing 
melatonin concentrations led to a prolongation of the lag-phase and 
a reduction of maximum rate of formation of conjugated dienes. 
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Fig. 4. Scavenging of the stable free radical DPPH by a-tocopherol 
and melatonin. To a 100 uM ethanolic solution of DPPH, 100 (iM 
melatonin or 50 uM a-tocopherol were added and the decrease of 
DPPH absorption was monitored at 517 nm every 2 s. 
from a series of redox reactions [26] within the lipid phase. 
Since a retarding effect of melatonin due to redox inactivation 
of copper can be excluded from the result of competitive 
copper reduction by melatonin and tocopherol, melatonin 
must enter the lipid phase of LDL to prevent oxidation in 
this case. Since using 10 times less ethanol in the assay led 
to essentially the same effect, the possibility can be ruled out 
that ethanol (0.5 vol% used for disperging melatonin into the 
aqueous solution) might increase melatonin solubility in LDL. 
Our results therefore indicate a continuous exchange of 
melatonin between the aqueous environment and the LDL 
lipid phase during the whole oxidation period with incorpo-
ration of very low quantities into LDL. Melatonin thus could 
act as an amphiphilic chain breaking antioxidant in a lipid 
environment, by scavenging peroxyl radicals, either derived 
directly from AAPH, or indirectly from copper.This is sup-
ported by recent findings which indicate a considerable solu-
bility in aqueous medium in the millimolar range [27]. 
Our observation that melatonin, compared to tocopherol, is 
rather unreactive against DPPH (Fig. 4), confirms a recent 
report that melatonin cannot scavenge radicals of low reac-
tivity (such as superoxide or, in this work, DPPH), but will 
react easily with more reactive species [13], such as lipid per-
oxyl or alkoxyl radicals. Thus melatonin is obviously a less 
potent and less lipophilic antioxidant than a-tocopherol, al-
beit it exerts its effects in the lipid phase of LDL, resulting in 
moderate prolongation of the lag-phase and decrease of prop-
agation rate. In the paper cited above it is speculated that 
melatonin might change the properties of the outer phospho-
lipid layer of LDL thereby reducing the overall mobility of the 
reactants or the accessibility of lipids to initiators of lipid 
peroxidation. Although this is in line with our observation 
that the effect of melatonin is not limited to the lag-phase, 
our finding that the LDL molecule cannot be loaded with 
melatonin in significant quantities contradicts this hypothesis. 
It is most unlikely that incorporation of much less than one 
melatonin molecule, among several hundreds of other mole-
cules that constitute the LDL surface [16] is sufficient for a 
distinct change of the surface properties of all LDL particles. 
Furthermore, a structural effect of melatonin would equally 
affect all phases of oxidation, or even dominate during the 
lag-phase. However, we show that the effect of melatonin 
addition is most prominent during propagation but small dur-
ing the lag phase. The moderate reactivity against radicals and 
the low melatonin concentration and persistence in LDL fully 
explain the effects observed. 
Based on our results a more differentiated concept of the 
antioxidant effect of melatonin is proposed: the assumed lip-
ophilicity of melatonin is not high enough to permit accumu-
lation in the lipid phase without constant supply from sur-
rounding bulk aqueous solution. Moreover, its antioxidant 
activity is considerably lower than that of a-tocopherol. Giv-
en the concentrations of melatonin in aqueous medium re-
quired to exhibit a significant protection of LDL against lipid 
peroxidation as compared to the in vivo situation, we exclude 
a significant modulating role of endocrine melatonin as an 
antioxidant for in vivo lipid peroxidation processes. However, 
an indirect role via regulation of other antioxidant defense 
systems by melatonin [13,28,29] cannot be ruled out. 
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